Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support

Bone Marrow Transplantation

Volumn 23, Issue 9, 1999, Pages 967-969

  Sezer, O ^a   Schmid, P ^a   Schweigert, M ^a   Heider, U ^a   Eucker, J ^a   Harder, H ^a   Sinha, P ^a   Radtke, H ^b   Possinger, K ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Amyloidosis; High dose chemotherapy; Nephrotic syndrome; Peripheral blood stem cell transplantation

Indexed keywords

AMYLOID; ANTINEOPLASTIC AGENT; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN; VINCRISTINE;

ADULT; AMYLOIDOSIS; ARTICLE; BONE MARROW; CASE REPORT; EDEMA; HUMAN; KIDNEY BIOPSY; MALE; MORBIDITY; MORTALITY; NEPHROTIC SYNDROME; PERIPHERAL BLOOD STEM CELL; PLASMA CELL; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; PROTEINURIA; SERUM; STEM CELL TRANSPLANTATION; URINE;

EID: 0032951404     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701765     Document Type: Article

References (14)

1. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. New Engl J Med 1997; 337: 898-909.
2. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32: 45-59.
3. Kyle RA, Gertz MA, Greipp PR et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. New Engl J Med 1997; 336: 1202-1207.
4. Majolino I, Marceno R, Pecoraro G et al. High-dose therapy and autologous transplantation in amyloidosis-AL. Haematologica 1993; 78: 68-71.
5. Comenzo RL, Vosburgh E, Falk RH et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: survival and responses in 25 patients. Blood 1998; 91: 3662-3670.
6. San Miguel JF, Garcia-Sanz R, Gonzales M, Orfao A. Immunophenotype and DNA cell content in multiple myeloma. Baillière's Clin Haematol 1995; 8: 735-759.
7. Hawkins PN, Peters AM, Vigushin DM et al. SAP scintigraphy and turnover studies demonstrate regression of amyloidosis. Nucl Med Commun 1993; 14: 259-260.
8. Levy Y, Belghiti-Deprez D, Sobel A. Treatment of AL amyloidosis without myeloma. Ann Med Interne Paris 1988; 139: 190-193.
9. Persey MR, Lovat LB, Apperley JF et al. Intensive chemotherapy for AL amyloidosis. Br J Rheumatol 1996; 35 (Suppl. 1): 12 (Abstr.).
10. Dhodapkar MV, Jagannath S, Vesole D et al. Treatment of AL-amyloidosis with dexamethasone plus alpha interferon. Leuk Lymphoma 1997; 27: 351-356.
11. Gertz MA, Lacy MQ, Lust JA et al. Phase II trial of high-dose dexamethasone for previously treated primary systemic amyloidosis. Blood 1998; 92 (Suppl. 1): 107a (Abstr.).
12. Goldman JM, Schmitz N, Niethammer D, Gratwohl A. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998. Accreditation Sub-Committee of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21: 1-7.
13. McElroy EA, Witzig TE, Gertz MA et al. Detection of monoclonal plasma cells in the peripheral blood of patients with primary amyloidosis. Br J Haematol 1998; 100: 326-327.
14. Guillaume B, Straetmans N, Jadoul M et al. Allogeneic bone marrow transplantation for AL amyloidosis. Bone Marrow Transplant 1997; 20: 907-908.